Check-Cap to expand manufacturing capacity

By staff writers

October 21, 2021 -- Israeli clinical-stage medical diagnostics company Check-Cap announced it is expanding its manufacturing capacity for the production of C-Scan, a colorectal cancer screening test, to support U.S. pivotal trials.

C-Scan uses an ultra-low dose x-ray capsule; an integrated positioning, control, and recording system; and proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is noninvasive and requires no sedation, the company said.

Check-Cap said it expects to launch the U.S. trials toward the end of the first quarter of 2022.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking